Lung Cancer
Conditions
Brief summary
The tumor associated CA-125antigen for diagnosis and follow-up of ovarian cancer was well defined. Increased serum CA125 level may have many diagnoses other than ovarian cancer, including breast, colorectal and lung cancer. 80% lung cancer patients were diagnosed at advanced stage. Malignant pleural effusion secondary to lung cancer represented the condition of cancer cell involved pleura. The CA-125 level may reflect the extent of tumor involved in pleura (tumor burden), it could be correlated with the prognosis. This study was performed to examine the properties of CA-125 by measuring pleural and blood CA-125 levels in lung cancer with or without malignant pleural effusion; meanwhile to examine whether the rate of decline in CA 125 during primary therapy as a surrogate indicator for survival.
Interventions
OTHERserum and pleural effusion CA-125 level
serum and pleural effusion(if exist) CA-125 are collected: * at time of diagnosis * every 3 month during treatment * stop at the progression or after 12 months
Sponsors
E-DA Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proved lung cancer
Exclusion criteria
* History of other cancers within the past 5 years * Pregnancy or breast milk feeding * TB pleuritis and peritonitis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The diagnostic Value of the cancer antigen-125 in lung cancer | 12months | 1. Comparison of CA-125 level in serum between lung cancer patients with or without malignant pleural effusion 2. The correlation between serum and pleural effusion CA-125 level |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The prognostic value of the cancer antigen-125 in lung cancer | 24 months | 1. Association of serum/ pleural effusion CA-125 level with Disease-Free Survival and Overall Survival 2. The correlation of CA-125 response at the 3rd , the 6th month between tumor lesion change 3. Analysis of survival in relation to CA-125 response |
Countries
Taiwan
Contacts
Primary ContactJiun-Ting Wu, MD
Outcome results
None listed